UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 4, 2016
Shire plc
_________________________________________________________________________
(Exact name of registrant as specified in its charter)
Jersey, Channel Islands
_________________________________________________________________________
(State or other jurisdiction of incorporation)
0-29630 | 98-0601486 |
(Commission File Number) | (IRS Employer Identification No.) |
5 Riverwalk, Citywest Business Campus, Dublin
24, Republic of Ireland
_________________________________________________________________________
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code +353 1 429 7700
_________________________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c)) |
Item 8.01. | Other Events |
Shire plc have issued the press release attached hereto as Exhibit 99.1 which is incorporated by reference herein.
Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits. The following exhibit is filed herewith:
99.1 | Press Release dated January 4, 2016 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SHIRE PLC | |||
By: | /s/ B Mordan | ||
Name: Bill Mordan | |||
Title: Company Secretary |
Dated: January 4, 2016
EXHIBIT INDEX
Number | Description |
99.1 | Press Release dated January 4, 2016 |
Exhibit 99.1
Press Release | ![]() |
www.shire.com |
Total Voting Rights
January 4, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with 5.6.1R of the Financial Conduct Authority's (the “FCA”) Disclosure Rules and Transparency Rules, notifies the market of the following:
As at December 31, 2015, the Company’s issued ordinary share capital comprised 592,548,261 ordinary shares of 5 pence each with voting rights and a further 8,527,703 ordinary shares held in treasury.
Therefore the total number of voting rights in the Company is 592,548,261. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Rules and Transparency Rules.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations | ||
Matthew Osborne | mattosborne@shire.com | +1 781 482 9502 |
Sarah Elton-Farr | seltonfarr@shire.com | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX